Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Essential thrombocythemia in a dog.

Takeshi Mizukoshi1, Yasuhito Fujino, Kuniyoshi Yasukawa

  • 1Sanyo Animal Medical Center, Okayama, Japan.

The Journal of Veterinary Medical Science
|December 6, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic variants of flavin-containing monooxygenase (FMO) 1 and FMO3 in 5887 dogs influenced oxygenations of probe substrates benzydamine, trimethylamine, and methyl p-tolyl sulfide.

Biochemical pharmacology·2026
Same author

Genetic variants in dog cytochrome P450 2B6 and their relevance to interindividual variability of oxidations of probe drug propofol.

Drug metabolism and disposition: the biological fate of chemicals·2025
Same author

Genetic variants of cytochrome P450 2C21 identified by screening 6344 dogs influenced oxidations of the probe drug omeprazole.

Biochemical pharmacology·2025
Same author

Efficacy of vincristine as a rescue therapy for canine histiocytic sarcoma.

The Journal of veterinary medical science·2024
Same author

Characterization of faecal microbiota and serum inflammatory markers in dogs diagnosed with chronic enteropathy or small-cell lymphoma: a pilot study.

Scientific reports·2024
Same author

Transcriptomic analysis of bone marrow specimens collected from Miniature Dachshunds diagnosed with non-neoplastic bone marrow disorders.

The Journal of veterinary medical science·2024

This report describes a rare case of essential thrombocythemia, a blood disorder characterized by high platelet counts, in a young Welsh Corgi. The dog presented with seizures and abnormal blood cell counts. After confirming the diagnosis through bone marrow analysis, the patient was treated with chemotherapy and steroids. The dog achieved full remission and remains healthy without ongoing treatment.

Area of Science:

  • Veterinary oncology and hematology research
  • Essential thrombocythemia clinical diagnostics within canine medicine

Background:

Veterinary clinicians often struggle to identify rare myeloproliferative disorders in young canine patients. Persistent elevation of blood platelets frequently presents diagnostic challenges for practitioners. No prior work had fully characterized the clinical progression of this specific condition in Welsh Corgis. That uncertainty drove the need for detailed case documentation. It was already known that megakaryocytic proliferation defines similar hematological anomalies. However, the specific presentation of seizures alongside these blood markers remained poorly understood. This gap motivated the current clinical report. The authors aimed to provide a comprehensive profile of this rare hematological diagnosis.

Purpose Of The Study:

The aim of this report is to document the clinical management of essential thrombocythemia in a young dog. This study addresses the scarcity of literature regarding this myeloproliferative disorder in canine patients. The authors sought to describe the diagnostic process for persistent platelet elevation. They intended to outline the specific chemotherapy regimen used for successful treatment. This work addresses the need for evidence-based approaches to rare hematological conditions. The researchers aimed to share findings from a successful remission case. They wanted to highlight the clinical signs that warrant further investigation in young animals. This report serves to improve awareness of this rare diagnosis among veterinary professionals.

Keywords:
myeloproliferative disordercanine hematologymegakaryocytic hyperplasiachemotherapy remission

Frequently Asked Questions

The researchers propose that the combination of busulfan and prednisolone chemotherapy successfully induced complete remission. This therapeutic regimen allowed the patient to achieve a healthy status within 100 days of the initial presentation.

Bone marrow examination was the diagnostic tool used to identify marked megakaryocytic hyperplasia. This procedure revealed specific morphologic abnormalities that confirmed the diagnosis of essential thrombocythemia.

The patient required this specific clinical evaluation because persistent thrombocytosis and neurological seizures suggested an underlying myeloproliferative process. The examination was necessary to distinguish this condition from reactive platelet increases.

The authors utilized hematological data, including platelet counts and cell morphology, to characterize the disease. These findings, alongside the bone marrow results, provided the evidence for the diagnosis.

Related Experiment Videos

Main Methods:

The clinical team performed a comprehensive evaluation of the two-year-old Welsh Corgi. Review approach involved analyzing persistent hematological markers over time. Practitioners conducted a detailed bone marrow biopsy to assess cellular architecture. They utilized standard laboratory staining techniques to visualize megakaryocytic morphology. The team monitored the patient for neurological symptoms during the diagnostic phase. Clinicians implemented a structured chemotherapy protocol following the confirmation of the diagnosis. They tracked the patient's recovery through serial blood count measurements. The authors synthesized these observations to document the progression of the disease.

Main Results:

The patient achieved complete remission exactly 100 days after the initial presentation. Initial laboratory assessments revealed marked thrombocytosis alongside eosinophilia and basophilia. The bone marrow analysis demonstrated significant megakaryocytic hyperplasia with distinct morphologic abnormalities. The dog also presented with moderate anemia at the time of referral. Following the initiation of chemotherapy, the patient showed a positive response to the treatment regimen. The dog has maintained good health without requiring further chemotherapy since the remission period. This case confirms that the chosen therapeutic combination effectively resolves the hematological imbalance. The findings demonstrate that long-term stability is attainable for young patients diagnosed with this condition.

Conclusions:

The authors propose that combination chemotherapy effectively manages this specific canine myeloproliferative disorder. Their findings suggest that busulfan and prednisolone can induce durable remission in young patients. This report indicates that complete hematological recovery is possible within one hundred days of starting therapy. The researchers highlight the importance of bone marrow evaluation for confirming such diagnoses. They suggest that long-term health can be maintained without continuous medication after achieving remission. The evidence implies that early identification of megakaryocytic abnormalities improves patient outcomes. This synthesis demonstrates that essential thrombocythemia is a manageable condition in dogs. The authors conclude that clinical vigilance remains vital for identifying these rare blood disorders.

The patient exhibited marked thrombocytosis, eosinophilia, basophilia, and moderate anemia. These specific blood cell abnormalities were key indicators of the underlying bone marrow dysfunction.

The authors propose that this case demonstrates the feasibility of achieving long-term remission in young dogs. They suggest that essential thrombocythemia should be considered in the differential diagnosis for persistent platelet elevation.